Cardio-Metabolic Risk Reduction
Functional medicine cardiometabolic care for patients in Michigan and Florida via telehealth.
Struggling with cholesterol, blood sugar, blood pressure, or weight trends moving in the wrong direction?
Not sure what is driving these changes, or how to get ahead of them before they progress?
Cardiometabolic disease often develops quietly through gradual shifts in insulin regulation, lipid metabolism, vascular health, inflammation, and daily lifestyle patterns.
You may be told your numbers are “not bad enough yet,” while still sensing that something is trending in the wrong direction. Family history, rising markers, weight resistance, fatigue, or blood sugar instability often signal an opportunity for earlier action.
At Barish Functional Medicine, this physician-led Cardiometabolic Risk Reduction service provides structured care in Michigan and Florida designed to identify early metabolic risk patterns, improve underlying physiology, and reduce long-term cardiovascular risk.
For patients who have previously worked with Dr. Barish, this reflects the same thoughtful, structured approach and is delivered through a dedicated functional medicine practice intentionally designed to support this model of care.
Care is delivered via telehealth across Michigan and Florida and is designed to complement, not replace, your primary care physician or cardiologist.
To understand the broader philosophy behind this approach, see What Is Functional Medicine.
Much of this work focuses on restoring physiologic function through nutrition, movement, sleep, and targeted nutrient support, with medication used selectively when needed.
Who This Service Supports
This service may be appropriate if you have:
Insulin resistance or prediabetes
Metabolic syndrome
High triglycerides or low HDL
Elevated ApoB or LDL particle number
Lipoprotein(a) elevation
LDL cholesterol above 190 mg/dL
A family history of premature cardiovascular disease
Hypertension with metabolic features
Fatty liver
Rising coronary artery calcium score
Persistent inflammatory markers
Blood sugar spikes or crashes after meals
Fatigue, cravings, or energy swings related to glucose patterns
Interest in continuous glucose monitoring (CGM) or real-time metabolic feedback
It is also appropriate for individuals in Michigan or Florida who want a prevention-forward, structured evaluation rather than waiting for overt disease progression.
How Cardiometabolic Imbalance Develops
Cardiometabolic disease is rarely caused by one isolated lab value.
It reflects interconnected physiologic shifts such as:
Adipocyte expansion and inflammatory signaling
Insulin resistance at muscle and liver
Elevated triglyceride to HDL ratios
Increased ApoB particle burden despite normal LDL cholesterol
Endothelial dysfunction and reduced nitric oxide signaling
Autonomic imbalance and sympathetic activation
Sedentary physiology
Sleep disruption and cumulative stress load
Patterns such as a rising triglyceride to HDL ratio, elevated ApoB, high-sensitivity CRP, or homocysteine may signal underlying vascular risk even when fasting glucose appears normal.
Inflammation frequently overlaps with cardiometabolic risk. For deeper discussion of immune and inflammatory contributors, see Immune Resilience & Inflammation Support.
The goal is not to chase isolated numbers. It is to interpret patterns and address root cause contributors within a systems-based framework.
These patterns do not only affect long-term risk. They often show up as day-to-day symptoms such as fatigue, post-meal energy dips, cravings, weight resistance, or difficulty maintaining metabolic stability.
Our Structured Framework
Predisposing Factors
Genetic predisposition, early metabolic programming, family history of cardiovascular disease, and baseline lipid or glucose patterns.
Triggers
Dietary shifts, weight gain, sedentary patterns, sleep disruption, chronic stress, and environmental or behavioral changes that initiate metabolic drift.
Ongoing Drivers
Insulin resistance, inflammatory signaling, lipid particle changes, endothelial dysfunction, autonomic imbalance, and oxidative stress patterns that sustain and amplify cardiometabolic risk.
This framework supports structured, sequential care by distinguishing what set the stage, what initiated change, and what is currently driving physiology forward.
Testing Used Thoughtfully
Testing in this Michigan and Florida functional medicine cardiometabolic program is layered and context-driven.
Core markers often include:
Lipid panel
ApoB
Lipoprotein(a) measured in nmol/L
Triglyceride to HDL ratio
Fasting insulin
Hemoglobin A1c
High-sensitivity CRP
Uric acid
Liver enzymes
Homocysteine
Selective testing may include:
LDL particle number
Omega-3 index
RBC magnesium
Coronary artery calcium scoring
Carotid intima-media thickness (CIMT) testing (in select cases)
Sleep apnea screening
An LDL cholesterol value at or above 190 mg/dL raises concern for familial hypercholesterolemia and prompts evaluation and family screening. Genetic dyslipidemia is a clearance disorder, not a willpower issue, and early identification protects first-degree relatives.
Coronary artery calcium scoring is used to guide shared decision-making. A score above 100 strengthens prevention discussions but does not automatically dictate therapy. Decisions remain individualized, documented, and collaborative.
In select cases, additional vascular imaging such as carotid intima-media thickness (CIMT) testing may be considered based on individual risk patterns and clinical context.
For more detail on how testing is selected and interpreted, see How We Use Testing.
Genetics and Personalized Risk
Genetic variation influences cardiometabolic risk but does not predetermine outcome.
When clinically relevant, this service integrates:
Familial hypercholesterolemia patterns
Lipoprotein(a) elevation
APOE variants
MTHFR variants
COMT variation when stress reactivity or methyl donor sensitivity is present
Lipoprotein(a) is genetically determined in most individuals and contributes to both plaque formation and clot risk. When elevated, global risk reduction becomes more important and ApoB burden is addressed with greater precision.
Methylation influences vascular health, nitric oxide production, neurotransmitter balance, and homocysteine metabolism. Homocysteine serves as a functional marker of methylation efficiency. Optimization typically targets levels below 7 through careful nutrient repletion and lifestyle adjustment rather than automatic high-dose supplementation.
Genetic insights guide fine-tuning of therapy. They do not justify fear-based labeling or indefinite supplementation without biochemical indication.
For patients navigating hormonal influences on cardiovascular physiology, see Hormone Health.
Core Therapeutic Focus
Targeted supplementation can play an important supporting role in this work, alongside nutrition, movement, sleep, and broader metabolic strategy.
Personalized nutrition strategy to improve insulin sensitivity, lipid patterns, and inflammatory tone
Lipid optimization targeting ApoB reduction and triglyceride normalization using lifestyle and, when appropriate, medication
Structured movement prescription focused on metabolic health, cardiovascular conditioning, and reduction of sedentary time
Blood pressure physiology support including magnesium status, potassium intake, endothelial function, and sleep evaluation
Thoughtful integration of lifestyle, targeted supplementation, and when appropriate, guideline-directed therapies
Medication Intensity & Long-Term Strategy
The goal is to stabilize underlying physiology and reduce long-term cardiovascular risk through structured, layered care grounded in lifestyle and targeted physiologic support.
In some cases, medication intensity may be minimized when clinically appropriate and safe. In other cases, guideline-directed therapy remains an important part of risk reduction.
All medication decisions remain with the prescribing clinician and are made within the context of established cardiovascular standards of care.
The emphasis is on thoughtful integration, not replacement, of conventional therapy.
Relationship to Conventional Care
This functional medicine cardiometabolic service in Michigan and Florida complements conventional cardiovascular care.
It does not replace your primary care physician or cardiologist.
Emergency symptoms such as chest pain, acute neurologic deficits, or unstable arrhythmias require immediate conventional evaluation.
The emphasis is stabilization, optimization, and long-term risk reduction within established medical standards.
What to Expect
Care is organized around measurable progress.
Initial evaluation identifies pattern drivers and establishes baseline physiology.
Interventions are introduced in prioritized sequence rather than all at once.
Follow-up evaluation and laboratory reassessment are individualized based on clinical context, treatment goals, and the pace of change underway.
Trends are interpreted in context. LDL shifts during weight loss or omega-3 therapy are reviewed carefully before adjustment.
You will understand what is changing and why, and how each step fits into a larger prevention strategy.
If you are reviewing recent labs and want a structured second look at your cardiometabolic risk profile, a discovery consultation may be an appropriate next step.
Cardiometabolic Risk Reduction FAQs
-
An LDL cholesterol value at or above 190 mg/dL raises concern for familial hypercholesterolemia, especially with premature family history. This warrants structured evaluation and screening of first-degree relatives.
-
Lp(a) is a genetically influenced cardiovascular risk marker present in nearly one in five individuals. Measurement is reasonable at least once in adulthood, particularly with family history of early heart disease.
-
A score above 100 strengthens the risk discussion but does not automatically mandate medication. Absolute risk, ApoB burden, family history, and prevention category are considered before therapy decisions are made. Shared decision-making guides the final plan.
-
Structured nutrition, movement, sleep optimization, and stress regulation can meaningfully improve cardiometabolic markers. In advanced disease, lifestyle is layered alongside appropriate medical therapy.
-
No. This service complements conventional cardiovascular care and supports coordinated prevention in Michigan and Florida.
-
This service supports both prevention and risk reduction. It is often used to identify early metabolic patterns before disease develops, but it can also be applied alongside conventional care in individuals with established cardiovascular risk.
-
No. Medication decisions are individualized and based on overall cardiovascular risk, family history, imaging, laboratory patterns, and patient preferences. In some cases, improving metabolic health and lifestyle patterns may reduce the need for medication intensity. In other cases, evidence-based therapies remain an important part of risk reduction.
Summary
Cardiometabolic Risk Reduction is a structured, genetics-informed functional medicine service designed to identify early metabolic drift, address root cause contributors, and reduce long-term cardiovascular risk.
Care is delivered via telehealth in Michigan and Florida through a systems-based framework that integrates advanced lipid evaluation, insulin resistance support, and appropriate medical therapy in collaboration with conventional care.